CONTEXT THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CONTEXT THERAPEUTICS INC. (CNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.91 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 575.00K shares, a 46.23% decline year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.33M shares, a 6.65% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 30.00K shares, a 114.29% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.28M shares, a 163.91% increase from fiscal 2024.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.24M shares, a 31.13% increase from fiscal 2023.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 949.14K shares, a 6.64% increase from fiscal 2022.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 890.06K shares, a 84.71% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 575.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 2.91M shares 10-Q · filed 2026-08-05 | 2.94M shares derived: sum of 3 quarters · filed 2026-08-05 | 2.94M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 2.33M shares 10-Q · filed 2026-05-06 | 2.36M shares derived: sum of 2 quarters · filed 2026-05-06 | 2.36M shares derived: sum of 3 quarters · filed 2026-05-06 | 3.43M shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 30.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 30.00K shares derived: sum of 2 quarters · filed 2026-03-23 | 1.10M shares derived: sum of 3 quarters · filed 2026-03-23 | 3.28M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.07M shares derived: sum of 2 quarters · filed 2025-11-05 | 3.25M shares 10-Q · filed 2025-11-05 | 3.27M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 1.07M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 3.25M shares 10-Q · filed 2025-08-06 | 3.27M shares derived: sum of 3 quarters · filed 2025-08-06 | 3.62M shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 2.19M shares 10-Q · filed 2025-05-07 | 2.20M shares derived: sum of 2 quarters · filed 2025-05-07 | 2.56M shares derived: sum of 3 quarters · filed 2025-05-07 | 2.68M shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 14.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 370.04K shares derived: sum of 2 quarters · filed 2025-03-20 | 495.04K shares derived: sum of 3 quarters · filed 2025-03-20 | 1.24M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 356.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 481.04K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.23M shares 10-Q · filed 2024-11-06 | 1.23M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 125.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 874.57K shares 10-Q · filed 2024-08-07 | 874.57K shares derived: sum of 3 quarters · filed 2024-08-07 | 874.57K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 749.57K shares 10-Q · filed 2024-05-08 | 749.57K shares derived: sum of 2 quarters · filed 2024-05-08 | 749.57K shares derived: sum of 3 quarters · filed 2024-05-08 | 874.57K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-21 | 125.00K shares derived: sum of 3 quarters · filed 2024-03-21 | 949.14K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 125.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 949.14K shares 10-Q · filed 2023-11-09 | 949.14K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 125.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 949.14K shares 10-Q · filed 2023-08-09 | 949.14K shares derived: sum of 3 quarters · filed 2023-08-09 | 979.14K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 824.14K shares 10-Q · filed 2023-05-10 | 824.14K shares derived: sum of 2 quarters · filed 2023-05-10 | 854.14K shares derived: sum of 3 quarters · filed 2023-05-10 | 1.04M shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 30.00K shares derived: sum of 2 quarters · filed 2023-03-22 | 216.53K shares derived: sum of 3 quarters · filed 2023-03-22 | 890.06K shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 216.53K shares derived: sum of 2 quarters · filed 2022-11-09 | 890.06K shares 10-Q · filed 2022-11-09 | 960.31K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 186.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 860.06K shares 10-Q · filed 2022-08-11 | 930.31K shares derived: sum of 3 quarters · filed 2022-08-11 | |
| 2022-03-31 | 673.53K shares 10-Q · filed 2022-05-11 | 743.78K shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 70.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 481.86K shares 10-K · filed 2022-03-23 | ||
| 2021-09-30 | 411.61K shares 10-Q · filed 2021-12-02 | |||
| 2020-12-31 | 14.42K shares 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |